OC 1012

Drug Profile

OC 1012

Latest Information Update: 11 Oct 2006

Price : $50

At a glance

  • Originator OraPharma
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Stomatitis

Most Recent Events

  • 18 Feb 2003 OraPharma has been acquired by Johnson & Johnson
  • 11 Sep 2001 Phase-I clinical trials for Stomatitis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top